Background and aims 58 Lactulose is a common food ingredient and widely used as a treatment for constipation or 59 hepatic encephalopathy and a substrate for hydrogen breath tests. Lactulose is fermented by 60 the colon microbiota resulting in the production of hydrogen (H 2 ). H 2 is a substrate for 61 enteropathogens including Salmonella Typhimurium (S. Typhimurium) and increased H 2 62 production upon lactulose ingestion might favor the growth of H 2 -consuming 63
enteropathogens. We aimed to analyze effects of single-dose lactulose ingestion on the growth 64 of intrinsic Escherichia coli (E. coli), which can be efficiently quantified by plating and which 65
share most metabolic requirements with S. Typhimurium. 66 67 Methods 68 32 healthy volunteers (18 females, 14 males) were recruited. Participants were randomized for 69 single-dose ingestion of 50 g lactulose or 50 g sucrose (controls). After ingestion, H 2 in 70 expiratory air and symptoms were recorded. Stool samples were acquired at days -1, 1 and 14. 71 We analyzed 16S microbiota composition and abundance and characteristics of E. coli 72
isolates. 73 74
Results 75 Lactulose ingestion resulted in diarrhea in 14/17 individuals. In 14/17 individuals, H 2 -levels 76 in expiratory air increased by ≥ 20 ppm within 3 hours after lactulose challenge. H 2 -levels 77 correlated with the number of defecations within 6 hours. E. coli was detectable in feces of all 78 subjects (2 x 10 2 -10 9 CFU/g). However, the number of E. coli colony forming units (CFU) 79 on selective media did not differ between any time point before or after challenge with 80 sucrose or lactulose. The microbiota composition also remained stable upon lactulose 81 exposure. 82 83
Conclusion 84 Ingestion of a single dose of 50 g lactulose does not significantly alter E. coli density in stool 85 samples of healthy volunteers. 50 g lactulose therefore seems unlikely to sufficiently alter 86 growth conditions in the intestine for a significant predisposition to infection with H 2 -87 consuming enteropathogens such as S. Typhimurium (www.clinicaltrials.gov NCT02397512). 88 Introduction 89 Humans coexist with trillions of microbes on their body surfaces, collectively referred to as 90 microbiota. One of the key benefits these microbes confer to their host is colonization 91 resistance (CR), i.e. protection against invasion and infection by pathogens. It is conceivable 92 that during gut colonization, the pathogen has to compete with the resident intestinal 93 microbiota for nutrients and binding sites (nutrient-niche hypothesis) (1, 2). Yet, the 94 mechanistic details underlying the protective effect by the microbiota have not been fully 95 elucidated. 96
Several perturbations can disrupt colonization resistance. Antibiotic treatment can disturb the 97 intestinal microbiota, predisposing the host to infections with enteric pathogens including 98
Salmonella Typhimurium (S. Typhimurium) and Clostridium difficile in humans (3) and in a 99 murine model (1, 4, 5) . Likewise, according to the nutrient-niche hypothesis, providing the 100 ecosystem with an additional nutrient should also open new niches, which might reduce 101 colonization resistance for certain pathogens. Effects of long-term and short-term (< 1 day) 102
perturbations might thereby differ since long-lasting interventions will trigger complex 103 secondary responses of the gut ecosystem. 104
The disaccharide lactulose is used as a food ingredient (named galacto-fructose) (6, 7) and as 105 a prescription or over-the-counter medication for constipation (8) or hepatic encephalopathy 106 in individuals with liver cirrhosis (9) . The lactulose breath test uses lactulose to diagnose 107 small intestinal bacterial overgrowth (10). As lactulose cannot be absorbed during the passage 108 through the host's small intestine (11), it reaches the large intestine where it enriches the 109 nutrient pool available to the gut microbiota. After arrival, lactulose is fermented by certain 110 gut microbiota members resulting in the production of short chain fatty acids (SCFA), 111
hydrogen (H 2 ) and methane (12, 13) . The production of these compounds explains the 112 laxative properties and also the side effects (abdominal pain and bloating) of this drug. Based 113 on these observations, it seems likely that the intake of lactulose might significantly alter 114 nutrient availability in the colon and thereby change the colonic microbiota composition. 115
Effects of short-term lactulose exposure on the gut microbiota have been insufficiently 116 studied. 117
We hypothesized that lactulose may also promote gut luminal growth of Enterobacteriaceae 118 like S. Typhimurium or Escherichia coli (E. coli). E. coli shares most metabolic requirements 119 of S. Typhimurium and growth of E. coli in stool samples is considered a surrogate for 120 favorable growth conditions of enteropathogens such as S. Typhimurium (14) . In contrast to 121 S. Typhimurium, E. coli can grow on lactulose, i.e. by taking up and degrading this 122 disaccharide. However, E. coli might also benefit directly or indirectly from the sugar 123 monomers galactose and fructose, which are released upon degradation of lactulose by certain 124 members of the gut microbiota (15, 16) Short-term exposure to lactulose might therefore be a model for a disease mechanism with a 131 defined manipulation of the intestinal environment, potentially altering the microbiota 132 composition and affecting susceptibility to enteric infections. Thus, we hypothesized that the 133 intake of lactulose might further promote gut luminal growth of Enterobacteriaceae such as 134 E. coli and S. Typhimurium. These effects might manifest rapidly since previous studies 135 demonstrated alterations in microbiota composition within 24 hours after dietary interventions 136 (22) (23) (24) (25) . Thereby, a single lactulose dose will allow monitoring direct effects of this 137 intervention, avoiding the complexity of secondary physiological and microbiological 138 compensatory responses upon long-term exposure. 139
In this study, we aimed at monitoring short-term effects of lactulose intake on human 140
volunteers upon a single lactulose dose. We tested for preferential growth of Enterobacteriae 196 To assess effects on the resident gut microbiota, fecal samples were collected one day before, 197 one day after, and two weeks after lactulose or sucrose exposure ( Figure 2 Schieritz&Hauenstein, Laufen, Switzerland) were added to each stool sample. The samples 255
were mixed using the tissue lyser (Qiagen) (3 min, 30Hz) and heated for 5 min at 95°C. Next, 256 samples were again mixed using the tissue lyser (3 min, 30Hz), centrifuged at full speed for 1 257 min and the supernatants were transferred to a new 2 ml microcentrifuge tube. The pellet was 258 suspended in 200 µl of Lysis Buffer (20mg/ml lysozyme (Sigma-Aldrich); 20mM Tris•HCl, 259 pH 8.0; 2mM EDTA; 1.2% Triton) and incubated at 37°C for 30 min. Afterwards, 500 µl of 260 Buffer ASL were added to each sample followed by mixing using the tissue lyser (3min, 261 30Hz) and heating the suspension for 5 min at 95°C. All samples were mixed again using the 262 tissue lyser (3vmin, 30Hz) and centrifuged at full speed for 1 min. The supernatants were 263 transferred to the same 2 ml tube than used before. Half of an InhibitEX tablet (provided in 264
Kit) was added to each sample and tubes were vortexed immediately until the tablet was 265 completely suspended. Next, samples were incubated for 1 min at room temperature, 266 centrifuged at full speed for 3 min and supernatants were transferred into a new 1.5 ml 267 microcentrifuge tube. The sample were again centrifuged at full speed for 3 min. Meanwhile, 268 35 μ l of proteinase K (provided in Kit) was added to a new 2 ml tube and supernatants from 269 previous centrifugation step were transferred to the 2 ml tube containing the proteinase K. 200 270 μ l of Buffer AL were added and samples were vortexed for 15 sec and incubated at 70°C for 271 10 min. The next steps were performed according to the manual instructions. The final elution 272 step was performed using 100 μ l Buffer AE (pre-heated to 70°C) added to the membrane, 273 then samples were incubated for 1 min at room temperature and centrifuged at full speed for 1 274 min to elute DNA. 275 276
Library preparation and sequencing for microbiota composition analysis 277
The 16S rRNA gene libraries were produced using the NEXTflex® 16S V4 Amplicon-Seq 278
Kit 2.0 (Barcodes 1-96; Bioo Scientific, Austin, Texas, USA). The input concentration of 279 genomic DNA was adjusted to 30 ng/µl for each PCR reaction. The library preparation was 280 performed following the manufacturer's instructions with the differences that the reaction 281 volume was reduced to 25 µl and a modified primer pair was used for the first PCR reaction. 282
Instead of the original primer pair 515f-806r, the degenerative primer 515F (5′-283 GTGYCAGCMGCCGCGGTAA-3′) and 806rB (5'-GGACTACNVGGGTWTCTAAT-3'), as 284 described in (32, 33) were used. The first PCR reaction was performed using Q5 High-285
Fidelity DNA Polymerase (BioConcept, NEB, Allschwil, Switzerland) under the following 286 cycling conditions: 1) initial denaturation: 95°C for 4 min; 2) denaturation: 95°C for 30 sec; 287
3) annealing: 56°C for 30 sec; 4) extension: 72°C for 90 sec; 5) final extension: 72°C for 4 288 min. Cycles 2-4 were repeated 8 times. After each reaction, the PCR products were cleaned 289 up using AMPure XP magnetic beads (Beckman Coulter SA, Nyon, Switzerland). The clean 290
PCR products were eluted in 20 µl of resuspension buffer and used in a second PCR reaction 291 for producing multiplexed samples, respectively. The quantity of the amplicons was measured 292 by a Qubit 3.0 fluorometer (Thermo Fisher Scientific). The quality of the amplicons was 293 evaluated using a Fragment Analyzer (Advanced Analytical, Ankeny, IA, USA). The length 294 of the barcoded amplicons was approximately 450 bp. The amplicons were pooled at 295 equimolar concentrations and diluted to a final concentration of 60 ng DNA per 20 µl before 296 loading on the Illumina MiSeq platform. Sequencing was performed at 2 x 250 bp read length 297 at the Functional Genomics Center Zurich. 298
Microbiota composition analysis 299
Initial analyses were performed using USEARCH (version 9.1.13) using custom scripts that 300 performed the following steps: paired reads were merged and quality-filtered using the 301 fastq_mergepairs command with default settings. Merged reads were filtered using the 302 fastq_filter command (-fastq_maxee 1.0) and only merged reads with perfect primer matches 303 and a minimum length of 100 bp were selected. Sequences were de-replicated using the 304 fastx_uniques and clustered into operational taxonomic units (OTUs) at 97% with chimera 305 removal using the cluster_otus command (-minsize 2). OTU abundances for each sample 306
were quantified using the usearch_global command (-strand both; -id 0.97). 2). After lactulose exposure, H 2 levels in expiratory air gradually increased for the next 90 min 378 and remained at this level for most individuals until the end of the observation period (180 379 min, Figure 4 ). H 2 levels varied widely (0-146 ppm); for three individuals of the lactulose 380 intervention group, H 2 levels in expiratory air never increased for more than 20 ppm over 381 baseline; these individuals are by definition H 2 non-producers (10). 382
For 14 out of 32 individuals (5 in the sucrose group, 9 in the lactulose group) methane (CH 4 ) 383 measurements were also taken ( Figure 4B ); for technical reasons, only the last 14 individuals 384
included into our study could be tested. However, only a single individual had increased CH 4 385 levels at baseline (15 ppm) and for no individual CH 4 levels exceeded 10 ppm over baseline. 386
For the three H 2 non-producers no CH 4 measurements were available. 387 H 2 levels in expiratory air correlated with number of defecations (p=0.024, Figure 4C ); 388 correlation analysis with stool consistency (BSS) revealed a non-significant trend (p=0.052, 389 Figure 4D ), suggesting that the intestinal response to lactulose was associated with H 2 390 production. 391 Bacterial growth in stool samples of lactulose and sucrose treated subjects 399 We tested whether lactulose ingestion and exposure of the intestine to excess H 2 increases 400 levels of E. coli and related Enterobacteriaceae in stool samples. Consistency of collected 401 stool samples (as judged by in inspection of collected material) was similar at all time points 402
(day -1, day 1 and day 14), arguing against significant confounding by sample dilution. Stool 403 samples were plated on selective media to quantify E. coli one day before (baseline), one day 404 after, and two weeks after disaccharide exposure ( Figure 5 ). At all time points, no difference 405 in bacterial numbers could be detected ( Figure 5A -C). Variation within the two groups was 406 high, with bacterial densities ranging from 3 x 10 2 to 10 9 colony forming units (CFU) per g 407 fecal sample in the control group and 2 x 10 2 to 8 x 10 8 CFU per g in the lactulose group 408
( Figure 5A -C). 409 CFU counts remained stable over time and no difference for time points could be detected in a 410 paired analysis (p>0.05 for all comparisons, Wilcoxon matched pairs signed-rank test). We 411 found highly significant correlations of the number of CFUs at baseline, day 1 and day 14 in 412 the group with lactulose treatment ( Figure 5D -F), indicating stability of E. coli population size 413 over time and upon lactulose perturbation. 414 As expected, E. coli counts were high, illustrating the abundance of E. coli in the microbiota 420 of healthy individuals. Considering the similar H 2 metabolism in E. coli and related organisms 421 (e.g. S. Typhimurium, Yersiniae, Campylobacter, Shigellae (17-21) our data argue against a 422 pronounced effect of increased H 2 levels on the growth of potential invading enteropathogens. 423
In line with this interpretation, the number of CFU at the day after lactulose exposure (or the 424 ratio of CFU between time points) did not correlate with maximum H 2 levels in expiratory air 425 at the intervention day ( Figure S1A ). 426
Number of CFUs or ratios of CFUs between days also did not correlate with number of 427 defecations after lactulose exposure ( Figure S1B ). We noted a positive correlation between 428 CFU and stool consistency (BSS) and the ratio of CFUs on day -1: day 1 in the control group 429
but not in the lactulose group ( Figure S1C ). 430
No Salmonella enterica colonies were detected in any of the stool samples, as judged from the 431 absence of color-less colonies on the MacConkey agar plates. 432 433 Phylogenetic analysis of stool isolates 434 To confirm species affiliation of isolated Enterobacteriaceae, bacterial strains from 30 435 participants at one day after treatment were analyzed by sequencing the 16S rRNA gene. 436
Sequences were classified using the basic local alignment search tool (BLAST). All bacteria 437 isolated from MacConkey agar were found to belong to the family of Annotated human bacterial isolates were tested for resistance against different antibiotics. 451
Seven antibiotics (imipenem, cefepim, gentamicin, kanamycin, ciprofloxacin, and 452 trimethoprim/ sulfamethoxazole) from 5 classes (carbapenems, cephalosporins, 453 aminoglycosides, fluoroquinolone and folic acid synthesis inhibitors) were chosen according 454
to known genetic determinants of resistance in Enterobacteriaceae to evaluate resistance 455 status in environmental settings (35). 456
All bacterial strains tested were susceptible to imipenem, cefepime, and kanamycin (Table  457 S2). Bacterial resistance against ampicillin was common (11 out of 30 strains, 37%) followed 458 by sulfamethoxazole/trimethoprim (7 out of 30 strains, 23%), ciprofloxacin (2 out of 30 459 strains, 7%) and gentamicin (1 out of 30 strains, 3%). Five bacterial strains were resistant to 460 two or more antibiotics (Table S2 ). No extended spectrum beta-lactamase producing strains 461
were identified. 462 463 Stability of microbiota upon lactulose exposure 464 We used 16S rRNA gene sequencing to analyze the taxonomic composition of the intestinal 465 microbiota after lactulose challenge. Overall, we observed no significant difference in 466 bacterial diversity between lactulose and sucrose treated individuals at day 1 and day 14 467 compared to pre-treatment conditions ( Figure 7A ). The microbiota composition was also 468 highly similar between lactulose and sucrose treatment. An example for phylum level 469 compositions is provided in Figure 7B . No significant shift in the taxonomic composition 470 was detected at any taxonomic level (paired false discovery rate (FDR)-corrected Wilcox 471 tests). 472 We observed intra-individual shifts in the dissimilarity of microbial composition between the 473 different sampling time points (days -1, 1, 14). Nevertheless, the shifts were similar in size for 474 lactulose and sucrose treated individuals. Furthermore, we did not observe any clustering of 475 samples by treatment (principal coordinate (PCo); analysis Figure 7C ). Similarly, we detected 476 no significant intra-individual dissimilarity changes before and after lactulose/ sucrose 477 ingestion ( Figure 7D ). Additionally, there was no correlation between intra-individual 478 dissimilarity (i.e. dissimilarity between time points) and BSS or H 2 levels ( Figure 7E ). 479
Given the absence of a strong treatment-related effect on microbial composition, we sought to 480 assess the sources of variation in our data set. Usage of lactulose for the treatment of acute or chronic constipation is well established (38). 518
Recent randomized controlled trials used lactulose as a standard treatment for comparative 519 testing against sodium polyethylene glycol (PEG) (39, 40), sodium picosulfate (39) and 520
Chinese or Pakistan herbal medicine (41, 42) . Effects of PEG were stronger than lactulose in a 521
Cochrane meta-analysis (43) and PEG or liquid paraffin were more effective in children (44) 522 even though these differences are small and possibly not clinically relevant. Cost-523 effectiveness of PEG and lactulose was virtually identical (45). Interestingly, lactitol might be 524 similarly effective, but more palatable with lesser side effects than lactulose (46). 525
We are not aware of a recent placebo-controlled randomized controlled trial for one-time 526 application of lactulose in young healthy individuals. Thus, our study provides valuable 527
information on the effectiveness of lactulose in healthy individuals. We observed diarrhea (i.e. 528
≥3 bowel movements in 6 hours) in 14 out of 17 (82%) of healthy participants ingesting 529 lactulose which was accompanied by at least moderate borborygmi, bloating, flatulence (14 530 out of 17, 82% for each symptom) and abdominal pain (8 out of 17, 47%). 531 532 Methane levels in expiratory air and H 2 non-producers 533 A fraction of patients and healthy individuals contain a methanogenic organism such as 534
Methanobrevibacter smithii (47). Hydrogenotrophic methanogens use 4 molecules of H 2 and 535 1 molecule of carbon dioxide (CO 2 ) to produce 1 molecule of methane (CH 4 ) (48). Due to this 536 additional metabolization step, the CH 4 peak will be delayed and due to the 4:1 ratio of H 2 537 and CH 4 , the methane peak will be at a lower level compared to H 2 . Therefore, a cut-off of 10 538 ppm for CH 4 is suggested (10). Furthermore, individuals with a methanogenic microbiota 539
usually have increased levels of CH 4 even at baseline, but fail to produce measurable H 2 upon 540 appropriate testing (10). In our analysis, methane measurements from only 14 individuals 541
were available and only for one person, methane levels exceeded the threshold of 10 ppm. 542
Our study included three H 2 non-producers (18%) without any increase in H 2 levels, well 543
within the expected range of 2-43% in healthy individuals or patients (49). However, no 544 methane measurements for these individuals are available. 545 546 Correlation of symptoms with H 2 levels 547
The healthy human intestine contains 30-200 ml (average 100 ml) gas, which mainly consists 548 of H 2 , CO 2 and CH 4 (10, 50). Both, H 2 and CH 4 are exclusively produced by the bacterial 549 microbiota (47). 550
Our study found a significant association of peak H 2 -levels with severity of diarrhea upon 551 lactulose challenge in healthy individuals, arguing for a relationship between H 2 -production 552 and symptoms after lactulose challenge. In our study, no significant effects of a single dose of 50 g lactulose on microbiota 566 composition could be detected after 1 day or after 14 days. Previous diet intervention studies 567
showed that short-term macronutrient shifts reversibly alter gut microbiota composition 568 within 24 hours even though broad patterns of microbiota composition similarities 569 (enterotypes) remain stable (22) (23) (24) (25) . Our PCo analysis showed that lactulose challenge did not 570 significantly alter the microbial composition since similar patterns of small-scale shifting 571
were observed for lactulose and sucrose, alike (day 1 and day 14). Instead, our data argue for 572 a stability of microbiota compositions with daily variations dominating over changes due to a 573 single intervention with 50 g lactulose, even though diarrhea was observed in the majority of 574 individuals. However, the data of this study provides no information about short-term 575 microbiota compositional changes immediately after lactulose challenge, nor about site-576 specific effects within the small intestine or the right-sided colon. 577 578 Effects of lactulose on the risks for intestinal infections 579 Prebiotics are food ingredients, which are neither digested nor degraded in the stomach or 580 small intestine, but fermented by the gut microbiota, leading to a selective stimulation of the 581 growth of certain intestinal bacteria and may thereby reap potential benefits for the host (58). 582
Lactulose, along with inulin and other oligosaccharides are considered prebiotics and 583
Lactobacillus and Bifidobacterium are considered significant target genera for the associated 584 prebiotic effects (58, 59) . 585
Since over 50 years, lactulose has been considered the "bifidus factor", increasing fecal 586
Bifidobacterium counts (60). A number of subsequent studies have confirmed increased 587
intestinal content of Bifidobacterium (61-67) and Lactobacillus (61, 64) in human stool 588 samples upon lactulose exposure. Those studies relied on conventional microbiological 589 techniques and did not address the overall composition of the intestinal microbiota. 590
Furthermore, in contrast to our study, lower dosages of lactulose (5-20 g) and longer exposure 591 times (4-8 weeks) were used, potentially explaining differences to our results. In fact, effects 592
on Bifidobacterium stool densities were weaker and not significantly differed from controls in 593 an 8-day study (68). However, short-term effects of lactulose on the intestinal microbiota have 594 not been tested previously. No "bifidus factor" effects were observed in our study and 595 differences in the time of lactulose exposure might explain this discrepancy. 596
Fermentation of lactulose is not limited to Lactobacillus and Bifidobacterium. Glucosidases 597 and bacterial transporters for lactulose are abundant in a large number of intestinal bacteria 598
including Cronobacter, Enterococcus, Escherichia, Klebsiella, Pseudomonas, and 599
Streptoccoccus spp., which were able to grow on lactulose as the sole carbon source (13). One 600 recent study addressed effects of feeding mice with lactulose for two weeks: The authors 601 noted a decrease in pH and an increase in short chain fatty acids in the colon. In the same 602 mice, an increase in Proteobacteriacae and Actinobacteria including Bifidobacterium and a 603 decrease in Firmicutes was observed. An increase in Helicobacter and Akkermansia spp. 604 content was interpreted to be secondary to increased mucin production. Similar to our study, 605 no increase in E. coli content was observed (69). These changes were accompanied by an 606 increase in Bifidobacteriae, Lactobacillus spp. and Enterobacteriacae. In our study, we found 607 a remarkable stability of the microbiota upon lactulose perturbation with 50 g lactulose 608 resulting in diarrhea in >80% of participants. In fact, day to day variation in the control group 609
were as big as variations in the experimental group and only approximately 3% of the 610 variance can be explained by lactulose treatment (not shown In our study we were aiming to establish an experimental model for improved growth 620 conditions for Enterobacteriace. In vivo data from our group with a murine colitis model 621
suggested that the initial growth of S. Typhimurium within the first day depended on the 622 presence of enzymes enabling hydrogen utilization (18). Better growth conditions for S. 623
Typhimurium would suggest a higher susceptibility for bacterial infections upon lactulose 624
exposure. This might be relevant for patients with liver cirrhosis which are highly susceptible 625
to bacterial infections (75) and for whom lactulose remains the first-line drug for treatment 626 and prevention of hepatic encephalopathy (9). 627
In our study, we did not find an increase in E. coli levels one day after lactulose application 628 even though E. coli could potentially benefit from H 2 produced upon lactulose ingestion. In 629 agreement with our results, no clinical data support an increased risk of enterobacterial 630 infections upon lactulose exposure. One reason for this could be that intrinsic E. coli are part 631 of metabolic networks in biofilms in the large intestine and might still depend on metabolic 632 contributions from other bacteria (according to the "Restaurant" hypothesis) (76), which 633 limits any stimulatory effects of H 2 and further studies for the metabolization of lactulose in 634 the intestine are warranted. 635
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